Scientific poster - Analytical performance of the Lumipulse® G β-Amyloid 1-40 Plasma and Lumipulse® G β-Amyloid 1-42 Plasma RUO assays
Poster presented at the AAIC 2022
On March 30, 2022, we announced the availability of the Lumipulse G β-Amyloid 1-40 Plasma <RUO> and Lumipulse G β-Amyloid 1-42 Plasma <RUO> assays, allowing fully automated quantitative measurement of β-amyloid1-40 and β-amyloid1-42, respectively, in human plasma. Having these biomarkers available on the LUMIPULSE® G platform enables researchers and clinical research professionals to further study the clinical utility of these markers individually and in combination (β-amyloid1-42 / β-amyloid1-40 ratio) on the Lumipulse platform that has the required throughput and meets the regulatory requirements to support a possible future routine use.
Here we report on the analytical performance of the newly developed Lumipulse G β-Amyloid 1-40 Plasma <RUO> and Lumipulse G β-Amyloid 1-42 Plasma <RUO>, determined on the first commercial lots. The aim of the study, presented at the AAIC 2022, was to determine the performance of several analytical parameters, including amongst others precision, sensitivity, linearity, and potential impact of interfering substances. The analytical performance studies demonstrate – amongst other characteristics – low variability and high sensitivity enabling reliable measurement of β-amyloid1-40 and β-amyloid1-42 in K2EDTA plasma in a Research Use Only context.
Authors of the poster:
Rosina Degrieck, Manu Vandijck, Mario Denoyette, Jarne Delanote, Maarten De Jonge, Bart De Decker, Nathalie Le Bastard, Ina Vandenbroucke.
Download your copy of the poster here
Our doors are open - contact us
We encourage partnerships dedicated to advancing neurodegeneration diagnostics.